Estrogens Interactions

Safety of concomitant use has not been established and use is not recommended.

Source: NLP:raloxifene hydrochloride

Other 5-HT1 agonists have additive vasospastic effects. Coadministration within 24 hours of rizatriptan benzoate is contraindicated.

Source: NLP:rizatriptan benzoate

Concomitant use with lenalidomide may increase the risk of thrombosis. Use with caution after benefit-risk assessment.

Source: NLP:lenalidomide

Estrogens produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

Source: NLP:acarbose

May decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:betamethasone sodium phosphate and betamethasone acetate

Increases risk of hypercalcemia when used concomitantly. Increase frequency of calcium concentration monitoring.

Source: NLP:calcium chloride

Concurrent administration may cause hypercalcemia. Monitor plasma calcium concentrations.

Source: NLP:calcium gluconate

Increases biliary cholesterol secretion and may counteract the effectiveness of chenodiol.

Source: NLP:chenodiol

Cholestyramine may delay or reduce the absorption of estrogens.

Source: NLP:cholestyramine

Cholestyramine may delay or reduce the absorption of estrogens.

Source: NLP:cholestyramine powder for suspension

Cholestyramine may delay or reduce absorption of estrogens.

Source: NLP:choleystyramine light

May elevate plasma total cortisol levels and affect test accuracy. Stop estrogen-containing drugs 4-6 weeks before COSYNTROPIN testing to allow cortisol binding globulin normalization.

Source: NLP:cosyntropin

Caution advised with concomitant use. Hepatotoxicity has occurred more often in women over 35 years receiving concurrent estrogen therapy.

Source: NLP:dantrolene sodium

Estrogens may decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Source: NLP:depo-medrol, lidocaine, isopropyl alcohol

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Source: NLP:dexamethasone

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Source: NLP:dexamethasone intensol

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

Source: NLP:empagliflozin, metformin hydrochloride

Increased levels of corticosteroid-binding globulin increasing bound inactive fraction. May require reduction in corticosteroid dosage when initiated and increased amounts when terminated.

Source: NLP:fludrocortisone acetate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:fosphenytoin sodium

Estrogens may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Source: NLP:glyburide

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Source: NLP:glimepiride

Estrogens may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Source: NLP:glipizide

Griseofulvin may enhance hepatic metabolism of estrogens, reducing effectiveness and causing menstrual irregularities. Alternate birth control may be indicated.

Source: NLP:griseofulvin

CYP inducing drugs increase activity of ALAS leading to induction of ALAS1 through feedback mechanism, counteracting PANHEMATIN therapy.

Source: NLP:hemin

Large doses of estrogens may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs render tissues partly resistant to hyaluronidase action.

Source: NLP:hyaluronidase

May increase serum cortisol-binding globulin, reducing hydrocortisone efficacy; may require dose increase.

Source: NLP:hydrocortisone

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:hydrocortisone sodium succinate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart-szjj

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Source: NLP:insulin degludec

May decrease blood glucose lowering effect of insulin glargine; dosage increases and increased glucose monitoring may be required.

Source: NLP:insulin glargine

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin glulisine

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin human

May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.

Source: NLP:insulin lispro

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Source: NLP:insulin lispro-aabc

Mutual inhibition of effects; β-blockers should be used cautiously in hyperreactive airways patients, with preference for β1-selective agents.

Source: NLP:ipratropium bromide and albuterol sulfate

Estrogens increase serum thyroxine-binding globulin, potentially decreasing free levothyroxine. Patients without functioning thyroid gland may require increased thyroid dose.

Source: NLP:levothyroxine, liothyronine

May increase serum thyroxine-binding globulin concentration, resulting in initial transient increase in FT4 followed by decreased serum T4.

Source: NLP:levothyroxine sodium

Estrogens may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Source: NLP:linagliptin and metformin hydrochloride

Oral estrogens may increase serum thyroxine-binding globulin concentration, altering T3 serum transport. Closely monitor thyroid hormone parameters.

Source: NLP:liothyronine sodium

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

Source: NLP:metformin

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Source: NLP:metformin er 500 mg

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

Source: NLP:metformin hydrochloride

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

Source: NLP:metformin hydrochloride extended-release tablets

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

Source: NLP:metformin hydrochloride tablet

Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Source: NLP:methylprednisolone acetate

Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:methylprednisolone sodium succinate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:extended phenytoin sodium

Delay and reduce absorption of prasugrel's active metabolite due to slowed gastric emptying. Consider parenteral antiplatelet agent alternative.

Source: NLP:prasugrel

Estrogens decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Source: NLP:prednisolone sodium phosphate

Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Source: NLP:prednisone

Safety of concomitant use has not been established; concomitant use is not recommended.

Source: NLP:raloxifene

Rifampin decreases estrogen exposure. Advise patients to change to non-hormonal birth control methods during rifampin therapy.

Source: NLP:rifampin

Higher doses of estrogens reduce clearance of ropinirole; starting or stopping hormone replacement therapy may require ropinirole dose adjustment.

Source: NLP:ropinirole

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

Source: NLP:sitagliptin and metformin hydrochloride

Oral estrogens may reduce the serum IGF-1 response to SOGROYA, potentially requiring higher SOGROYA dosages.

Source: NLP:somapacitan-beco

Oral estrogens may reduce the serum IGF-1 response to NGENLA. Patients receiving oral estrogen replacement may require higher NGENLA dosages.

Source: NLP:somatrogon-ghla

Larger doses of somatropin may be required in women using oral estrogen.

Source: NLP:somatropin

Increases serum thyroxine-binding globulin (TBg), decreasing free levothyroxine (T4) in patients without functioning thyroid glands. May require increased thyroid dose.

Source: NLP:thyroid, porcine

Concomitant use not recommended; hypotensive effects may be cumulative.

Source: NLP:tizanidine

Concomitant use not recommended; hypotensive effects may be cumulative.

Source: NLP:tizanidine hydrochloride

Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.

Source: NLP:triamcinolone acetonide

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:triamcinolone acetonide extended-release injectable suspension

Increase hepatic cholesterol secretion and may counteract the effectiveness of ursodiol.

Source: NLP:ursodiol

Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol effectiveness.

Source: NLP:usodiol